´ëÇÑÀ̽ÄÇÐȸ
Àλ縻 Çмú´ëȸ ¾È³» ÇÁ·Î±×·¥ »çÀüµî·Ï ÃÊ·ÏÁ¢¼ö Çà»çÀå ¾È³» ¼÷¹Ú ¾È³»
 
2012³â Á¦8Â÷ ´ëÇÑÀ̽ÄÇÐȸ Ãá°èÇмú´ëȸ
 
ŸÀÌƲ Çмú´ëȸ > ÇÁ·Î±×·¥
 
ȸ»ö¶ó¿îµå»ó´Ü

Time Room A Room B Room C
08:30~09:00 Registration
09:00~09:10 Opening
09:10~10:10 Symposium I : Immune tolerance in solid organ transplantation
10:10~10:40 Coffee break
10:40~12:00 Symposium II : Issues about live organ donor
12:00~12:25 Symposium III : KSOT Report
12:25~13:00 General assembly
13:00~14:00 Luncheon Symposium
14:00~15:20 Concurrent symposium I
(Kidney I)
Concurrent symposium I
(Liver I)
Concurrent symposium I
(Advances in immunologic test)
15:20~15:40 Coffee break
15:40~17:00 Concurrent symposium II
(Kidney II)
Concurrent symposium II
(Liver II)
Concurrent symposium II
(Coordinator Session)


  ³»¿ë ÁÂÀå/¿¬ÀÚ
08:30~09:00 Registration
09:00~09:10 Opening ¼­º¸¾ç(¿µ³²ÀÇ´ë)
09:10~10:10
Symposium I :
Immune tolerance in solid organ transplantation
ÁÂÀå:±è»óÁØ(¼­¿ïÀÇ´ë),
±èÀ¯¼±(¿¬¼¼ÀÇ´ë)
09:10~09:30 Monitoring of immune tolerance ÀÌ»óÈ£(°æÈñÀÇ´ë)
09:30~09:50 Tolerance induction protocol in kidney transplantation ¾çÀç¼®(¼­¿ïÀÇ´ë)
09:50~10:10 Tolerance induction protocol in liver transplantation À¯Èñö(ÀüºÏÀÇ´ë)
10:10~10:40 Coffee Break
10:40~12:00
Symposium II :

Issue about live organ donor
ÁÂÀå:ÇÑ´öÁ¾(¿ï»êÀÇ´ë),
ä±Ç¹¬(¿ø±¤ÀÇ´ë)
10:40~11:00 »ýü±âÁõÀÚÀÇ ¼úÈÄ ÇÕº´Áõ (½ÅÀå°ú °£) Á¤»ó¿µ(Àü³²ÀÇ´ë)
11:00~11:20 »ýü±âÁõÀÚÀÇ Á¤½ÅÀû ½ºÆ®·¹½º À±ÀÍÁø(°Ç±¹ÀÇ´ë)
11:20~11:40 »ýü±âÁõÀÚ¿¡ ´ëÇÑ ¼úÀü ±³À° ¹× ¼úÈÄ °ü¸® ÇÁ·Î±×·¥ º¯³âÀÓ(¼­¿ï´ëº´¿ø)
11:40~12:00 Panel Discussion
12:00~12:25
Symposium III:

KSOT Report
ÁÂÀå:°­Á¾¸í(ÇѾçÀÇ´ë),
±èµ¿±¸(°¡Å縯ÀÇ´ë)
12:00~12:10 CAST °á»êº¸°í ±èÀ¯¼±(¿¬¼¼ÀÇ´ë)
12:10~12:25 Àå±âÀ̽ĵî·Ï ½Ã¹ü»ç¾÷ ±è¸í±Ô(¼­¿ïÀÇ´ë)
Concurrent Symposium I
14:00~15:20
Concurrent Symposium I (Kidney 1)

Cardiovascular disease and kidney transplantation
ÁÂÀå:¹Ú¼º±¤(ÀüºÏÀÇ´ë),
¾È±Ô¸®(¼­¿ïÀÇ´ë)
14:00~14:20 Obesity and cardiovascular mortality Çã¿ì¼º(¼º±Õ°üÀÇ´ë)
14:20- 14:40 Pre and post-op care in severely atherosclerotic patients ±èÇüÅÂ(°è¸íÀÇ´ë)
14:40~15:00 Cardiac evaluation before KT in ESRD patients Çã±ÔÇÏ(¿¬¼¼ÀÇ´ë)
15:00~15:20 Lipid lowering agent in kidney transplantation ½Åº´Ã¶(Á¶¼±ÀÇ´ë)
14:00~15:20
Concurrent Symposium I (Liver 1)
Current status of DDLT
ÁÂÀå:À̼®±¸(¼º±Õ°üÀÇ´ë),
¼­°æ¼®(¼­¿ïÀÇ´ë)
14:00-14:40 Split liver transplantation  
14:00~14:20 Outcome ¼Û±â¿ø(¿ï»êÀÇ´ë)
14:20~14:40 Optimal regulation of allocation À̱¤¿õ(¼­¿ïÀÇ´ë)
14:40~15:00 Marginal donor ÇÑ¿µ¼®(´ë±¸°¡Å縯)
15:00~15:20 Discussion Ȳ½Å(¿ï»êÀÇ´ë),
À¯¿µ°æ(°¡Å縯ÀÇ´ë)
14:00~15:20
Concurrent Symposium I:

Advances in immunologic test
ÁÂÀå:±èº´Ã¢(¸Þ¸®³îº´¿ø),
¼Òº´ÁØ(¿ø±¤ÀÇ´ë)
14:00~14:20 PRA and donor-specific HLA antibody ¹Ú¸íÈñ(¼­¿ïÀÇ´ë)
14:20~14:40 Detection of Anti-endothelial cell antibody °­Àº¼÷(¼º±Õ°üÀÇ´ë)
14:40~15:00 Method to detect cellular immune responses ¿ÀÀºÁö(°¡Å縯ÀÇ´ë)
15:00~15:20 Flow cytometry to measure the level of HLA or ABO antibodies ¿øµ¿ÀÏ(°æºÏÀÇ´ë)
15:20~15:40 Coffee Break
Concurrent Symposium II
15:40~17:00
Concurrent Symposium II (Kidney 2)

HBV infection in transplantation
ÁÂÀå:±è¼ºÈ¯(Á¶¼±ÀÇ´ë),
¾çö¿ì(°¡Å縯ÀÇ´ë)
15:40~16:00 Impact of anti-viral tx. on long-term outcome Á¤º´ÇÏ(°¡Å縯ÀÇ´ë)
16:00~16:20 Salvage therapy in lamivudine resistance ±èÂù´ö(°æºÏÀÇ´ë)
16:20~16:40 Immunosuppressive strategy in HBV (+) patients ÀÌ ½Ä(ÀüºÏÀÇ´ë)
16:40~17:00 Use of HBV (+) donors ÃÖ¼öÁø³ª(Àü³²ÀÇ´ë)
15:40~17:00
Concurrent Symposium II (Liver 2)

When to delist the patients
ÁÂÀå:±è¼øÀÏ(¿¬¼¼ÀÇ´ë),
Á¶Àç¿ø(¼º±Õ°üÀÇ´ë)
15:40~16:00 HCC ÃÖ±âÈ«(¿¬¼¼ÀÇ´ë)
16:00~16:20 Acute on chronic / fulminant hepatic failure ÀÓ¿µ (¿ï»êÀÇ´ë)
16:20~16:40 Cardiopulmonary criteria ÃÖ¿ë¼±(¿¬¼¼ÀÇ´ë)
16:40~17:00 Infectious status ±è»óÀÏ(°¡Å縯ÀÇ´ë)
15:40~17:00
Concurrent Symposium II
(Coordinator Session)
ÁÂÀå:ÇÏÈñ¼±(¼­¿ï¾Æ»êº´¿ø),
±èº¹³à(»ï¼º¼­¿ïº´¿ø)
15:40~16:00 Overview of the MELD and PELD score ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë)
16:00~16:20 Pitfalls of emergency status 2A in LT Àü°æ¿Á(¼¼ºê¶õ½ºº´¿ø)
16:20~16:40 Role of KODA for deceased donors º¹ÃáÈñ(Çѱ¹Àå±â±âÁõ¿ø)
16:40~17:00 ÄÚµð³×ÀÌÅÍ ÃÑȸ
ȸ»ö¶ó¿îµå ÇÏ´Ü
 
Ä«ÇǶóÀÌÆ®